Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.68 AUD | -2.16% | 0.00% | +56.32% |
04-30 | Genetic Signatures Appoints Interim CEO | MT |
04-28 | Genetic Signatures' Sales Drop in Fiscal Q3 | MT |
Sales 2024 * | 10.1M 6.53M 9M | Sales 2025 * | 26.2M 16.95M 23.35M | Capitalization | 130M 83.84M 116M |
---|---|---|---|---|---|
Net income 2024 * | -17M -11M -15.15M | Net income 2025 * | -6M -3.88M -5.35M | EV / Sales 2024 * | 10.9 x |
Net cash position 2024 * | 20M 12.94M 17.83M | Net cash position 2025 * | 7M 4.53M 6.24M | EV / Sales 2025 * | 4.68 x |
P/E ratio 2024 * |
-7.39
x | P/E ratio 2025 * |
-19.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.08% |
1 day | -2.16% | ||
1 month | +0.74% | ||
3 months | +38.78% | ||
6 months | +36.00% | ||
Current year | +56.32% |
Managers | Title | Age | Since |
---|---|---|---|
John Melki
CEO | Chief Executive Officer | - | 02-12-31 |
Karl Pechmann
DFI | Director of Finance/CFO | - | 23-06-25 |
Douglas Millar
CTO | Chief Tech/Sci/R&D Officer | - | 01-02-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anthony Radford
BRD | Director/Board Member | - | 15-09-14 |
Caroline Waldron
BRD | Director/Board Member | - | 22-05-12 |
Michael Aicher
BRD | Director/Board Member | 64 | 14-01-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 0.68 | -2.16% | 1 662 |
24-04-30 | 0.695 | -0.71% | 107,446 |
24-04-29 | 0.7 | +2.19% | 96,719 |
24-04-26 | 0.685 | +0.74% | 71,242 |
24-04-24 | 0.68 | 0.00% | 75,859 |
Delayed Quote Australian S.E., May 30, 2024 at 11:54 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.32% | 84.17M | |
+7.15% | 217B | |
+6.60% | 183B | |
+9.86% | 131B | |
+24.32% | 106B | |
-0.95% | 62.16B | |
+11.04% | 51.02B | |
+4.81% | 50.89B | |
-1.43% | 40.16B | |
+24.40% | 31.44B |
- Stock Market
- Equities
- GSS Stock